Composite The Duke University Medical Center (DUMC) Clinical Trials Unit (CTU) proposes to address the key scientific areas of translational research and optimization of clinical management in children and adults, and prevention of mother to child transmission.The CTU and its affiliated Clinical Research Sites (CRS's) bring scientific leadership, a rich history of successful collaborative clinical research within networks, a strong and efficient organizational foundation for the conduct of rigorous clinical research, and access to growing numbers of underserved persons living with HIV/AIDS (PLWHA) in the US Southeast and Tanzania. The scientific leadership of the CTU and CRS investigators is reflected in their past participation in the Adult and Pediatric AIDS Clinical Trials Groups (ACTG's), and the expanding portfolio of NIH-funded research at DUMC and the Kilimanjaro Christian Medical Centre (KCMC). The three CRS's included in the CTU proposal each bring unique value and are highly motivated to perform the proposed work, and together they will constitute a formidable research enterprise. Their interactions will be guided by an administrative structure which supports a dynamic intellectual environment to enhance scientific creativity, clear roles and responsibilities for investigators and staff, facile and regular communications, harmonized standard operating procedures across CRS's which emphasize CTU accountability through quality management, and a strong commitment to serve the community of PLWHA. The clarity of CTU and CRS organization and operations will ensure that it operates efficiently to perform clinical research at the highest standard, with the ability to rapidly respond to evolving opportunities.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-SR-A (M2))
Program Officer
Pouliot, Eileen M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Lennox, Jeffrey L; Landovitz, Raphael J; Ribaudo, Heather J et al. (2014) Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med 161:461-71
Leger, Paul D; Johnson, Daniel H; Robbins, Gregory K et al. (2014) Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384. J Neurovirol 20:304-8
Haas, David W; Kwara, Awewura; Richardson, Danielle M et al. (2014) Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. J Antimicrob Chemother 69:2175-82
Johnson, Daniel H; Venuto, Charles; Ritchie, Marylyn D et al. (2014) Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 24:195-203
Lisasi, Esther; Kulanga, Ahaz; Muiruri, Charles et al. (2014) Modernizing and transforming medical education at the Kilimanjaro Christian Medical University College. Acad Med 89:S60-4
Touzard Romo, F; Smeaton, L M; Campbell, T B et al. (2014) Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175). HIV Clin Trials 15:246-60
Sulkowski, Mark S; Kang, Minhee; Matining, Roy et al. (2014) Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. J Infect Dis 209:658-67
Jacobson, Jeffrey M; Wang, Hongying; Bordi, Rebeka et al. (2014) A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy. J Acquir Immune Defic Syndr 66:399-406
Ribaudo, Heather J; Daar, Eric S; Tierney, Camlin et al. (2013) Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202. J Infect Dis 207:420-5
Bronke, Corine; Almeida, Coral-Ann M; McKinnon, Elizabeth et al. (2013) HIV escape mutations occur preferentially at HLA-binding sites of CD8 T-cell epitopes. AIDS 27:899-905

Showing the most recent 10 out of 11 publications